Brought to you by 
EyePoint created through merger of pSivida and Icon Bioscience
03 Sep 2020
Executive Summary
PSivida Corp. is acquiring closely held ophthalmic-focused Icon Bioscience Inc. to create a public specialty pharmaco to be named EyePoint Pharmaceuticals.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com